Telehealth Business Models: Cash-Pay, Subscription, and B2B

Quick answer

A telehealth business model is not simply a visit fee, subscription, or prescription-delivery offer. It is the connected system through which a business creates value, reaches a buyer, collects payment, delivers clinical access, covers variable costs, coordinates fulfillment, and gives the patient or sponsoring organization a legitimate reason to continue.

For most operators, the practical choices are cash-pay visits, recurring subscriptions, bundled programs, sponsored business-to-business access, or a hybrid. The right choice is the one in which payment timing fits the real patient journey and the costs triggered by enrollment, clinician work, support, and fulfillment.

That conclusion is editorial judgment, not a claim that one model is universally superior. A systematic review of 23 telehealth business-model studies found that value propositions, financial variables, and revenue streams were common components. It also concluded that different settings may require different models and that their effectiveness still needs practical evaluation. peer-reviewed literature

Telehealth Business Models in One View

Five archetypes cover many of the structures an operator is likely to evaluate:

These labels do not settle the economics. Two businesses can both call themselves subscription platforms while facing very different provider workloads, support obligations, fulfillment costs, and cancellation patterns.

The first operator question should therefore be: **What event creates a payment or cash collection, and which operational events create costs before or after it?**

• **Cash-pay visit:** The individual pays for a consultation or another clearly defined service event.
• **Subscription:** The individual or sponsor pays on a recurring schedule for defined access, services, or program participation.
• **Bundled program:** One payment or a payment plan covers a specified period and set of services.
• **Sponsored B2B access:** An employer, health plan, health system, or partner buys access or services for an eligible population.
• **Hybrid:** The business combines two or more payment paths, such as sponsored access plus individual visit fees.

Start With the Payment Event, Not the Technology

A video platform, asynchronous intake flow, or mobile application describes delivery technology. It does not explain the business model.

Map the operating sequence as separate events:

Do not collapse these events into a single word such as customer. A person who starts intake is not necessarily a paying user. A paying user is not necessarily eligible for any requested pathway. A prescription decision is not a shipment, and a shipment is not retention.

A testable hypothesis might be that moving payment earlier improves initial cash collection. The same change could also increase refunds, support contacts, or dissatisfaction when the requested pathway does not proceed. The worksheet must capture both sides.

Payment and cash-collection events are planning inputs, not accounting conclusions. Operators must model revenue recognition separately under their applicable accounting policies.

• A prospect encounters a message.
• The prospect starts an intake or creates an account.
• A payment is authorized or collected.
• A clinician reviews information or conducts a visit.
• An independent clinical decision is made.
• A laboratory, pharmacy, fulfillment, or support event may occur.
• Follow-up, refill, renewal, cancellation, or failed-payment events occur later.

Cash-Pay, Subscription, Bundle, B2B, and Hybrid Models

The following matrix is an original planning asset. Its questions are designed for operator input; they are not industry benchmarks.

Verified company disclosures illustrate how different these structures can be. LifeMD describes a direct-to-patient model combining proprietary technology, affiliated clinical services, pharmacy infrastructure, and operational systems. It reported approximately 328,000 active patient subscribers as of December 31, 2025. SEC filing That disclosure demonstrates one subscription-oriented configuration; it does not establish that subscriptions are more profitable or suitable for another operator.

Teladoc reports both B2B and direct-to-consumer channels and organizes its operations into Integrated Care and BetterHelp. It completed 17.1 million telehealth visits in 2025 across its channels. SEC filing This illustrates a multi-channel model, not comparative evidence about acquisition efficiency or clinical outcomes.

The Clinical Gate Belongs Inside the Business Model

Marketing may invite a person to explore a service. It cannot decide whether that person receives care, qualifies for a pathway, or receives a prescription.

One disclosed consumer platform connects patients with licensed healthcare professionals who may prescribe when clinically appropriate, uses licensed pharmacies for online fulfillment, and supports follow-up through an integrated platform. SEC filing The important structural point is the sequence: consumer acquisition, clinician access, an independent clinical decision, possible fulfillment, and follow-up are connected but distinct.

An operator-grade model should document:

Editorial judgment: if the business plan works only when nearly every paying prospect reaches a predetermined clinical outcome, the model contains a structural conflict that pricing language cannot repair.

• Where clinician review occurs.
• Whether payment happens before or after that review.
• What the customer has purchased if the requested pathway does not proceed.
• Which refund, support, or alternative-service workflow is triggered.
• How marketing, customer support, and clinical operations remain separated.

Provider Time Is a Core Variable Cost

Provider time is a variable delivery input even when the customer sees a flat price. Operators should separately estimate time for initial review, synchronous visits, documentation, follow-up, escalations, and nonclinical coordination. Multiplying an assumed average visit time by a wage rate is not enough if substantial work occurs outside the scheduled visit.

For each workflow, document what triggers provider work, how often it can recur, and whether the work occurs before or after payment. Use company-specific inputs rather than unsupported benchmark costs.

Where Pharmacy and Fulfillment Fit

A model might coordinate with licensed pharmacies, operate broader pharmacy infrastructure, or sell a service that does not involve product fulfillment. The supplied filings illustrate coordinated online fulfillment in one consumer platform and integrated pharmacy infrastructure in another. SEC filing SEC filing

For planning purposes, identify who owns each customer-facing obligation: inventory availability, payment collection, order status, delivery communication, refill coordination, cancellation, refund handling, and service recovery. Do not infer ownership or margins from the mere presence of pharmacy infrastructure.

A testable hypothesis could be that tighter operational integration shortens handoffs. It could also add working-capital requirements, fixed costs, or service responsibilities. Operators need their own data before treating either effect as established.

Acquisition Is a System, Not a CAC Number

Customer acquisition cost is an output of a defined measurement system, not a universal market constant. The system includes the audience, channel, message, landing experience, intake, payment event, clinical gate, and follow-up.

Patterns observed in a non-random internal sample of long-form direct-response creative included a high-attention opening followed by problem framing, a simplified explanation, an offer, reassurance, and a next step. **[Corpus note 1]** **[Corpus note 2]** **[Corpus note 3]** This is an observation about creative structure, not proof of conversion, revenue, retention, or scale.

A telehealth operator can turn that structural observation into a neutral message map:

The testable hypothesis is that clearer transitions reduce confusion. Measure that with the operator's own funnel, support, refund, and completion data. The corpus cannot establish the result.

• **Attention:** Why is this service relevant now?
• **Relevance:** Which access, convenience, or coordination problem is being addressed?
• **Explanation:** How does the service process work, without inventing a medical mechanism?
• **Offer:** What exactly is included, excluded, and charged?
• **Reassurance:** What should the user expect from privacy, support, cancellation, and the clinical gate?
• **Next step:** What action can the user take without implying a predetermined clinical result?

Offer Architecture Changes the Economics

Price presentation affects more than checkout. It changes cash timing, delivery obligations, refund exposure, and the period before a customer makes another continuation decision.

Patterns observed in a non-random internal sample included prepaid multi-unit offers, bonuses, guarantees, price anchors, and limited-availability framing near the purchase decision. **[Corpus note 4]** **[Corpus note 5]** **[Corpus note 6]** Their presence is not proof of conversion, retention, revenue, or scale.

For each offer, model:

A large upfront payment can improve initial cash position while creating longer delivery obligations. A low entry price can reduce purchase friction while leaving insufficient contribution to cover clinical and support work. Neither is automatically better.

• Gross cash collected before refunds.
• Payment fees, failed payments, refunds, and chargebacks.
• Services and fulfillment triggered immediately.
• Delivery obligations that remain after the refund window.
• Unused-service or cancellation handling.
• The next honest continuation decision.

Retention Must Follow the Service Journey

A billing interval is not a retention strategy. Retention should arise from continuing value such as access, follow-up, refill coordination, program continuity, or sponsor-level service—not from making cancellation obscure or escalating fear.

A disclosed consumer platform describes consistent follow-up capabilities, while another company reports an active-subscriber population. SEC filing SEC filing These disclosures illustrate operating components. They do not prove that a particular follow-up design causes retention.

Separate these metrics in the plan:

Then identify why each stakeholder continues. The patient and sponsoring buyer may value different things, and a pharmacy event is not interchangeable with continued clinical access.

• Eligible or enrolled person.
• Active user.
• Completed consultation or visit.
• Recurring payer.
• Refill or follow-up event.
• Retained sponsor account.

Direct-to-Consumer Versus Sponsored Distribution

Direct-to-consumer distribution usually places acquisition spending, message testing, checkout, and individual support close to the operator. Sponsored distribution adds a buyer that may be different from the user.

Teladoc says its Integrated Care customers include employers, health plans, hospitals, health systems, insurers, and other organizations. Approximately 102 million US members had access to one or more Teladoc services as of December 31, 2025. SEC filing

Access must not be treated as active use, a completed visit, retention, or revenue. In a sponsored model, track at least four separate units: contracting buyer, eligible population, registered or active users, and completed service events.

Editorial judgment: sponsored distribution can change who bears acquisition expense, but it does not eliminate acquisition. The work may shift toward contracting, implementation, member communication, partner enablement, and account renewal.

Telehealth Business Model Canvas and Economics Worksheet

Complete this canvas before writing a forecast:

The following equations are illustrative planning conventions, not standard accounting definitions. In every equation, **gross cash collected** means cash collected before refunds. Refunds are therefore subtracted once as a separate item.

**Contribution before acquisition for a defined period** = gross cash collected before refunds − refunds − provider cost − pharmacy or fulfillment cost − payment fees − other variable support costs for the same period.

**First-payment contribution** = gross cash collected from the first payment before refunds − refunds tied to that payment − all variable costs triggered through the first service period.

**Later monthly recurring contribution** = gross cash collected in a later month before refunds − refunds tied to that month − recurring variable delivery costs for that same month.

**Remaining acquisition balance after the first service period** = the greater of zero or acquisition spending − first-payment contribution.

**Illustrative later-period acquisition payback** = remaining acquisition balance ÷ later monthly recurring contribution.

Use that payback calculation only when later monthly recurring contribution is positive, sufficiently stable, and measured on the same monthly basis as the estimated payback period. If first-payment contribution already covers acquisition spending, the model indicates recovery within the first service period; it does not identify the exact day. Cash-pay and prepaid models with irregular later payments may require a period-by-period cash schedule instead of a monthly recurring formula.

Run conservative, base, and upside cases for continuation, service use, refunds, and failed payments. Those scenarios are planning assumptions, not predictions. Do not hide an uncertain retention assumption inside a single lifetime-value figure.

The decision rule is simple: choose an archetype only after identifying who pays, what triggers cash collection, what triggers clinical and fulfillment costs, and why someone would legitimately continue.

A Copy and Policy Risk Check

Patterns observed in a non-random internal sample included borrowed authority, celebrity-style framing, absolute outcomes, simplified biological explanations, and extreme urgency. **[Corpus note 7]** **[Corpus note 8]** **[Corpus note 9]** **[Corpus note 10]** This is a creative-risk observation, not performance evidence.

Before launch, review whether:

This checklist is marketing and policy analysis, not jurisdiction-specific legal advice or an assurance of compliance. The editorial judgment is that persuasive structure can be retained without relying on unsupported authority, invented mechanisms, or fear-driven pressure.

• Every objective claim has appropriate substantiation.
• Attributed expertise, testimonials, and endorsements are authentic and accurately presented.
• The copy avoids guaranteed or predetermined clinical outcomes.
• Urgency reflects a real operational condition.
• Guarantee terms match actual refund operations.
• Marketing does not blur the independent clinical gate.
• Privacy expectations match the intake and follow-up experience.
• Checkout clearly explains what the customer is buying.

Sources and Method Notes

Primary-source links appear beside the claims they support. Corpus notes describe a non-random internal sample and do not establish performance.

• **Corpus note 1.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 2.** Pattern observed in one item from Daily Intel's non-random Diabetes transcript sample; observational context, not conversion evidence.
• **Corpus note 3.** Pattern observed in one item from Daily Intel's non-random Hair transcript sample; observational context, not conversion evidence.
• **Corpus note 4.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 5.** Pattern observed in one item from Daily Intel's non-random Weight Loss transcript sample; observational context, not conversion evidence.
• **Corpus note 6.** Pattern observed in one item from Daily Intel's non-random Hair transcript sample; observational context, not conversion evidence.
• **Corpus note 7.** Pattern observed in one item from Daily Intel's non-random Sexual Wellness transcript sample; observational context, not conversion evidence.
• **Corpus note 8.** Pattern observed in one item from Daily Intel's non-random Sexual Wellness transcript sample; observational context, not conversion evidence.
• **Corpus note 9.** Pattern observed in one item from Daily Intel's non-random Diabetes transcript sample; observational context, not conversion evidence.
• **Corpus note 10.** Pattern observed in one item from Daily Intel's non-random Hair transcript sample; observational context, not conversion evidence.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Google helpful content guidance. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Telehealth marketing research library, Telehealth Advertising: What You Can Say, Target, and Track, Telehealth Landing Pages: 12 Pre-Intake Elements, Telehealth Trends 2026: A US Operator Evidence Map, GLP-1 market research, and Compliance and legal disclaimer. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.